Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Business Wire • May 21, 2026
Read articleAgenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Business Wire • May 21, 2026
Read articleAgenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Business Wire • May 15, 2026
Read articleAgenus (AGEN) Q1 Earnings and Revenues Miss Estimates
Zacks • May 12, 2026
Read articleAgenus: Q1 Earnings Snapshot
Associated Press • May 11, 2026
Read articleRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Zacks • May 11, 2026
Read article